Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 7, 2009; 15(21): 2651-2656
Published online Jun 7, 2009. doi: 10.3748/wjg.15.2651
Table 1 Characteristics of patients, tumors and treatment approach (mean ± SD)
Patients and tumor characteristicsValue
No. of patients255
Median age (yr)56.0 ± 13.2 (range, 18-89)
Gender (male/female)205/50
Disease (HCC/MHC/CCC)212/39/4
Background liver disease (HBV/HCV/no infection)168/5/82
Patients with liver cirrhosis n (%)172 (67.5)
Portal vein invasion (no/yes)25/230
Alphafetoprotein (0-5/5-400/> 400 ng/mL)88/92/75
Child-Pugh classification (A/B/C)231/22/2
ALT (U/L)47.6 ± 2.5
AST (U/L)54.7 ± 3.0
Total bilirubin (umol/L)27.4 ± 7.1
Serum albumin (g/L)38.9 ± 0.3
Tumor stage425
Number of tumors (uninodular/multinodular)148/107
Size of tumor (cm)5.1 ± 3.4 (range, 1.3- 20)
Diagnosis (histopathologic/clinical)215/210
Treatment350
Choice of approach (percutaneous/ laparoscopy/laparotomy)257/7/86
Combination with TACE or PEI (+/-)61/194
Table 2 Major complications after radiofrequency ablation
ComplicationNo. of complicationsDisease
Hepatic failure13HCCs
Thoracic complications108 HCCs, 1 CCC, 1 MHC
Tumor seeding3HCCs
Upper gastrointestinal bleeding1HCC
Intrahepatic abscess1HCC
Bile duct injury1HCC
Cardiac complication1HCC
Hyperglycemia5HCCs